about
Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study.Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled TrialUse of the 'Accountability for Reasonableness' Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country.Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic ExtractionHIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients.Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.Elective reconstruction of the ascending aorta for aneurysmal disease restores normal life expectancy. An analysis of risk factors for early and late mortality.Consequences of polyparasitism on anaemia among primary school children in Zimbabwe.Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis.Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications.Quality of abstracts of pilot trials in heart failure: A protocol for a systematic survey.Quality of pilot trial abstracts in heart failure is suboptimal: a systematic survey.Assessment of quality of obstetric care in Zimbabwe using the standard primipara.Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosisEffect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazidEvaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin ConcentrationsCurrent research toward optimizing dosing of first-line antituberculosis treatmentAdverse Drug Reactions in Paediatric In-Patients in a South African Tertiary HospitalEffect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosisPropagation of measurement errors in glomerular filtration rate determination: a comparison of slope-intercept, single-sample and slope-only methodsPharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosisEffects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosisQuantitative assessment of the activity of antituberculosis drugs and regimensEarly antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosisLow Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?
P50
Q34714716-E2341877-4220-4640-94E2-F4AB630CFA0BQ35071965-CBF6B898-18B9-467D-886D-AF0C33DA8964Q36152820-E0A9CC37-AC26-456E-8B21-13B13E215FFBQ36438900-D2969AE5-F29F-4045-8877-4127840B182FQ37287701-D3AD52DD-D508-437B-A525-57828B81533BQ38729024-8E508C1C-A783-4D94-B043-35282BD1A5FFQ38973113-2219D6A2-8151-4DAB-B388-2C5041E0D0B9Q43622771-CBD2D030-AC67-4EB2-A976-729E97EE6999Q46270345-092FCBAA-E897-4C25-AB86-F5E1D8670BD5Q50054098-12C50E0E-D797-4E2B-AFE1-43B59B2DECF3Q53692275-DC70F248-1600-4830-9829-F69A542B03BAQ54956587-9351E489-E6EB-45C2-8F04-C17A52374F5FQ55312423-E3CD6BD5-DDB6-439C-8524-5FD5E58A7EE1Q55491764-C0257C8D-2305-4D48-8BD8-E6069594FBA8Q56949160-B304DCBA-F0A0-4396-8D21-CAED66568ED4Q60364209-5CB6DC5A-DEB8-4E0E-82E8-19C20D2E2787Q60364210-2575856E-C98B-42A2-8BB6-13BAA76FA003Q60364214-90EAC1BF-1808-4DF9-872E-8F34F0E3959FQ90452601-87877C14-A5A2-4342-83F8-30A2D51D2349Q90806444-00AE9FE6-E3AF-4DCF-AFC9-F7E959727C2AQ91142093-C5B88FB2-3D4E-48A4-ADE5-700F3DA59C65Q91326116-E5ADAB1F-89E7-4157-B412-42A48DDE526EQ91611591-84B537E8-05B4-4E44-9FB8-62ABFB5AE774Q92393086-98DF7FA3-F01D-43D0-B98B-343848865FDBQ92486406-0427A960-B100-4293-A436-3EE7EC328A95Q92613648-65338DA6-6747-46ED-825E-D76E95007F99
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Maxwell T Chirehwa
@ast
Maxwell T Chirehwa
@en
Maxwell T Chirehwa
@es
Maxwell T Chirehwa
@nl
type
label
Maxwell T Chirehwa
@ast
Maxwell T Chirehwa
@en
Maxwell T Chirehwa
@es
Maxwell T Chirehwa
@nl
prefLabel
Maxwell T Chirehwa
@ast
Maxwell T Chirehwa
@en
Maxwell T Chirehwa
@es
Maxwell T Chirehwa
@nl
P106
P1153
35728258800
P21
P31
P496
0000-0002-1685-4882